Denton John Russel

Caris Life Sciences insider buys 4,184 shares at $24.09; stock down 36.9% from 52-week high but prior buy at CAI showed +59.2% 90-day return.

Denton John Russel purchased 4,184 shares of CAI at $24.09, increasing his holdings by 83.7% to 9,184 shares post-transaction. The timing follows a meaningful price decline: the stock trades at $24.80 (36.9% below its 52-week high of $39.30) and has fallen 18.6% over the past 30 days and 23.6% over 90 days. Notably, Russel's prior purchase at CAI on 2025-06-20 delivered a 59.2% return over 90 days, and his cross-ticker track record shows 100% win rate on buys with an average 90-day return of 59.2%. The company's fundamentals remain intact with revenue of $216.8M and net income of $24.3M in the latest quarter against a $7.0B market cap. This acquisition in a depressed environment mirrors his demonstrated pattern of well-timed accumulation at this ticker.

Insider Denton John Russel bought 7,500 shares of CAI at $21.00 on 2025-06-20, raising holdings to 123,591 shares.

Denton John Russel purchased 7,500 shares at $21.00, increasing his position by 6.5% to 123,591 shares post-transaction. The stock is trading at $25.94 as of 2025-06-23, just 3 trading days post-purchase. Caris Life Sciences is a recent listing, so historical price comparisons are not yet meaningful. The purchase represents a direct capital commitment, but without longer-term trading history or fundamental context, the materiality of this transaction relative to the insider's portfolio and the company's trajectory remains to be established.